Trials / Completed
CompletedNCT02242292
Study to Evaluate Efficacy and Safety of Oral Doses of Hyoscine Butylbromide for the Treatment of Occasional Abdominal Pain, Cramping, and Discomfort
A Double-blind, Placebo-controlled, Randomized, Parallel Group Study of the Efficacy and Safety of Oral Doses of 20 mg Hyoscine Butylbromide When Used On-demand up to 7 Episodes Over a Period of 6 Weeks for the Treatment of Occasional Episodes of Self-reported Abdominal Pain, Cramping, and Discomfort Associated With Cramping in an OTC-like Study Population
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 527 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study to determine whether hyoscine butylbromide can provide adequate symptomatic relief of a single episode - defined as lasting not longer than 1 day - and multiple episodes of abdominal pain or discomfort associated with cramping when used as needed
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hyoscine butylbromide | |
| DRUG | Placebo |
Timeline
- Start date
- 2006-04-01
- Primary completion
- 2007-01-01
- First posted
- 2014-09-17
- Last updated
- 2017-12-28
Source: ClinicalTrials.gov record NCT02242292. Inclusion in this directory is not an endorsement.